Literature DB >> 26378747

Treatment of Retinoblastoma in 2015: Agreement and Disagreement.

David H Abramson1, Carol L Shields2, Francis L Munier3, Guillermo L Chantada4.   

Abstract

The management of intraocular retinoblastoma is rapidly changing, and even recent reviews on the subject are behind existing practices. The 4 authors of this report collectively represent their management strategies with an emphasis on areas of agreement and disagreement. Ophthalmic artery chemosurgery and intravitreous chemotherapy have completely replaced external beam radiotherapy, reduced the use of systemic chemotherapy, and diminished enucleations by 90% without evidence of compromising patient survival.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26378747     DOI： 10.1001/jamaophthalmol.2015.3108

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


  72 in total

1.  Tumour size criteria for Group D and E eyes in the International Classification System for Retinoblastoma: effects on rates of globe salvage and high-risk histopathologic features.

Authors:  Jonathan W Kim; Sona N Shah; Sarah Green; John O'Fee; Benita Tamrazi; Jesse L Berry
Journal:  Acta Ophthalmol       Date:  2019-08-17       Impact factor: 3.761

2.  Lens Dose-Response Prediction Modeling and Cataract Incidence in Patients With Retinoblastoma After Lens-Sparing or Whole-Eye Radiation Therapy.

Authors:  Steven M Nguyen; Julian Sison; Marjorie Jones; Jesse L Berry; Jonathan W Kim; A Linn Murphree; Vanessa Salinas; Arthur J Olch; Eric L Chang; Kenneth K Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-12-08       Impact factor: 7.038

3.  Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma.

Authors:  David H Abramson; Armida W M Fabius; Jasmine H Francis; Brian P Marr; Ira J Dunkel; Scott E Brodie; Anna Escuder; Y Pierre Gobin
Journal:  Ophthalmic Genet       Date:  2017-01-17       Impact factor: 1.803

Review 4.  The Interdisciplinary Diagnosis and Treatment of Intraocular Tumors.

Authors:  Norbert Bornfeld; Eva Biewald; Sebastian Bauer; Petra Temming; Dietmar Lohmann; Michael Zeschnigk
Journal:  Dtsch Arztebl Int       Date:  2018-02-16       Impact factor: 5.594

Review 5.  The management of retinoblastoma.

Authors:  Ido D Fabian; Zerrin Onadim; Esin Karaa; Catriona Duncan; Tanzina Chowdhury; Irene Scheimberg; Shin-Ichi Ohnuma; M Ashwin Reddy; Mandeep S Sagoo
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

6.  Loss of fundus view as an indication for secondary enucleation in retinoblastoma.

Authors:  Jesse L Berry; Kaitlin Kogachi; Rima Jubran; Jonathan W Kim
Journal:  Pediatr Blood Cancer       Date:  2017-12-08       Impact factor: 3.167

7.  The Effect of Ophthalmic Artery Chemosurgery on Immune Function in Retinoblastoma Patients: A Single Institution Retrospective Analysis.

Authors:  Cheryl Fischer; Mary Petriccione; Stephanie Vitolano; Edith Guarini; Mary Elizabeth Davis; Ira J Dunkel
Journal:  J Pediatr Hematol Oncol       Date:  2017-10       Impact factor: 1.289

8.  Combined intra-arterial chemotherapy and intravitreal melphalan for the treatment of advanced unilateral retinoblastoma.

Authors:  Ting-Yi Liang; Xiu-Yu Zhu; Xu-Ming Hua; Xun-Da Ji; Pei-Quan Zhao
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

9.  ZNRD1-AS1 knockdown alleviates malignant phenotype of retinoblastoma through miR-128-3p/BMI1 axis.

Authors:  Guanghua Yang; Chen Zeng; Yang Liu; Dongliang Li; Juanjuan Cui
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

10.  The technique of superselective ophthalmic artery chemotherapy for retinoblastoma: The Garrahan Hospital experience.

Authors:  Flavio Requejo; Juan Marelli; Agustin Ruiz Johnson; Claudia Sampor; Guillermo Chantada
Journal:  Interv Neuroradiol       Date:  2017-11-09       Impact factor: 1.610
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.